Seven major varieties to focus on in 2019

The drug fair is coming at the end of 2018 Usually, the customers participating in the fair are looking for products that can be represented by domestic enterprises Therefore, the first drug imitation of domestic enterprises is the product most concerned by agents In 2018, the first imitated products approved for production include tegrilol tablet of Shenzhen xinlitai Pharmaceutical Co., Ltd., solina succinate tablet of Sichuan Guowei Pharmaceutical Co., Ltd., ibuprofen injection of Chengdu Yuandong biopharmaceutical Co., Ltd., flurbiprofen ester injection of Wuhan Da'an Pharmaceutical Co., Ltd., praxole hydrochloride of Zhejiang Jingxin Pharmaceutical Co., Ltd And so on It can be seen that the approval progress of domestic generic drugs began to accelerate in 2018 For the following seven varieties, the first copy of Xianda data v3.5 is worthy of attention The following products are not necessarily all agents, but also manufacturers may choose direct marketing All information is subject to the manufacturer's announcement 1 The original manufacturer of apixaban tablets: Bristol Myers Squibb competition first imitated enterprise: Sichuan Kelun Pharmaceutical Co., Ltd and Zhengda Tianqing Pharmaceutical Group Co., Ltd market potential: more than 200 million yuan Evaluation: Jiangsu Haosen Pharmaceutical Group Co., Ltd was included in the priority review, but did not enter the priority review finally It is Sichuan Kelun Pharmaceutical Co., Ltd and Zhengda Tianqing Pharmaceutical Group Co., Ltd that are approved to enter the clinical self-examination verification and the on-site verification plan of drug clinical trial data These two companies are likely to be approved for the first time In the future, the competition of this product is very fierce The products reported in the new four categories include Qilu Pharmaceutical (Hainan) Co., Ltd., Guangdong dongyangguang Pharmaceutical Co., Ltd., Dongguan yangzhikang Pharmaceutical Co., Ltd., Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd., Chengdu Beite Pharmaceutical Co., Ltd., Nanjing Zhengda Tianqing pharmaceutical Co., Ltd., Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., Jiang Xiqingfeng Pharmaceutical Co., Ltd 2 The original manufacturer of esmeralazole magnesium enteric coated tablets: AstraZeneca competes for the first imitation enterprise: market scale of Suzhou Teri Pharmaceutical Co., Ltd.: nearly 2 billion yuan evaluation: Suzhou Teri gets the priority review, also enters the clinical self-examination and verification, and enters the on-site verification plan announcement of drug clinical trial data, which is expected to be approved for the first imitation 3 Original manufacturer of celecoxib capsule: Pfizer competition first imitated enterprise: Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd and Jiangsu Hengrui Pharmaceutical Co., Ltd market scale: more than 700 million yuan Evaluation: the competition of this product is very fierce The manufacturers that have entered the priority review are Ouyi Pharmaceutical Co., Ltd., Qingdao Baiyang Pharmaceutical Co., Ltd., Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd and Jiangsu Hengrui Pharmaceutical Co., Ltd., but only Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd has entered the clinical self-examination and verification and entered the on-site verification plan of clinical trial data And Jiangsu Hengrui Pharmaceutical Co., Ltd 4 Original research manufacturer of wigletin tablets: Novartis market potential: 200 million competitive first imitators: Beijing Taide Pharmaceutical Co., Ltd., Nanjing Unocal Pharmaceutical Co., Ltd., Nanjing Unocal biomedical Group Co., Ltd Evaluation: for the moment, no manufacturer has been given priority review, and Beijing Taide and Nanjing Youke have simultaneously entered the on-site verification plan announcement of drug clinical trial data (No 22) From the acceptance number, Beijing Taide is ahead In addition, Zhengda Tianqing Pharmaceutical Group Co., Ltd and Jiangsu aosaikang Pharmaceutical Co., Ltd compete for the first imitation of another DPP4 drug, shagliptin tablets 5 Relying on the original research manufacturer of Kaoxi tablets: moshadong, the first imitator in competition: Qilu Pharmaceutical Co., Ltd market scale: more than 300 million yuan evaluation: Qilu pharmaceutical won the priority evaluation Chengdu Yuandong biopharmaceutical Co., Ltd has entered the clinical self-examination and verification, but has not yet entered the announcement of the on-site verification plan of the clinical trial data Qilu's progress is relatively ahead 6 Original manufacturer of sunitinib malic acid capsule: Pfizer competition first imitated enterprise: Sinopharm group Ouyi Pharmaceutical Co., Ltd market scale: more than 300 million yuan Evaluation: Jiangsu Haosen Pharmaceutical Group Co., Ltd and Sinopharm group Ouyi Pharmaceutical Co., Ltd entered the fourteenth batch of self inspection catalogue at the same time, but only Sinopharm group Ouyi Pharmaceutical Co., Ltd entered the on-site verification plan announcement of drug clinical trial data, with a slightly faster progress 7 Original manufacturer of linezolid tablets: Pfizer's first imitator: Jiangsu Haosen Pharmaceutical Group Co., Ltd and Shanghai desino biomedical Co., Ltd with market potential of more than 400 million yuan Evaluation: Chongqing Huabang Pharmaceutical Co., Ltd and Jiangsu Haosen Pharmaceutical Group Co., Ltd have both entered the priority review, but Jiangsu Haosen Pharmaceutical Group Co., Ltd and Shanghai Desano bio Pharmaceutical Co., Ltd have entered the clinical self inspection and verification catalogue and the announcement of the on-site verification plan of the clinical trial data of drugs From the perspective of progress, Jiangsu Haosen is ahead Other first imitated products worthy of attention are: arguletin benzoate tablets of Yabao Pharmaceutical Group Co., Ltd., bensulfobertastine tablets of Chongqing Huabang Pharmaceutical Co., Ltd., dutasteride soft capsules of Sichuan Guowei Pharmaceutical Co., Ltd., tropicanate citrate tablets of Zhengda Tianqing Pharmaceutical Group Co., Ltd., Hebei Renhe Yikang Pharmaceutical Co., Ltd., Jiangsu Haosen pharmaceutical Co., Ltd Pramipexole Succinate Tablets, rivaroxaban tablets of Zhengda Tianqing, tadalafei tablets of Changchun Haiyue Pharmaceutical Co., Ltd and Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., afatinib maleate tablets of Jiangsu Haosen Pharmaceutical Group Co., Ltd., pramipexole hydrochloride sustained release tablets of Jiangsu Hengrui Pharmaceutical Co., Ltd., Qilu Trimetazidine hydrochloride sustained release tablets declared by pharmaceutical Co., Ltd., Shenzhen Hanyu Pharmaceutical Co., Ltd and Jiangsu Hengrui Pharmaceutical Co., Ltd With the approval of generic drugs, diabetes drugs will enter the period of substitution of domestic products It is expected that many overstocked domestic generic drugs will be approved in 2019 Zhengda Tianqing, Hengrui and hausen are the main competitors of the first generic drugs, but they are usually direct sales teams There are not many manufacturers for agents to choose from The bidding and procurement policies of conformity evaluation show a trend, and the cost space of generic drugs is becoming less and less Under the two vote system, the pressure of tax bill processing and payment collection of agents further reduce the living space of agents Good products are not easy, agents and manufacturers and line and cherish.